RxDoctor Payments Data

Jeffrey Nassif, MD

Adult Reconstructive Orthopaedic Surgery · Cedar Rapids, IANPI 1336147800

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Pacira Pharmaceuticals Incorporated accounts for 60.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $18,970 and has fallen 96.6% since, to $650 in 2025.

$30,893in general payments, 2019–2025

Across 78 payments — averaging $396.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$19K
  • Maxx Orthopedics, Inc.$9K
  • Zimmer Biomet$2K
  • Stryker$661
  • Smith+Nephew$358
  • Arthrex$148
  • plus $217 from 5 others
$1,400in research payments, 2019–2025

Across 5 payments — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Zimmer Biomet$1K

What the payments were for

  • Consulting fees$16,04052%
  • Speaking & faculty fees$7,54024%
  • Travel & lodging$3,04910%
  • Food & beverage$4,26414%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$346,132
Medicare patients
488
Services billed
5,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$6,522
Oxycodone Hcl120$617
Meloxicam356$583
Carbidopa-LevodopaCarbidopa/Levodopa12$512
Nabumetone46$371
Tramadol Hcl157$368
Amoxicillin305$357
Clindamycin Hcl60$344
Tamsulosin Hcl12$303
Cephalexin87$260
Gabapentin75$201
Ondansetron OdtOndansetron40$143
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$135
Tranexamic Acid28$125
Famotidine34$113

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →